These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24376654)

  • 1. Agonistic anti-TIGIT treatment inhibits T cell responses in LDLr deficient mice without affecting atherosclerotic lesion development.
    Foks AC; Ran IA; Frodermann V; Bot I; van Santbrink PJ; Kuiper J; van Puijvelde GH
    PLoS One; 2013; 8(12):e83134. PubMed ID: 24376654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice.
    Foks AC; Engelbertsen D; Kuperwaser F; Alberts-Grill N; Gonen A; Witztum JL; Lederer J; Jarolim P; DeKruyff RH; Freeman GJ; Lichtman AH
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):456-65. PubMed ID: 26821944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells.
    Douna H; Amersfoort J; Schaftenaar FH; Kröner MJ; Kiss MG; Slütter B; Depuydt MAC; Bernabé Kleijn MNA; Wezel A; Smeets HJ; Yagita H; Binder CJ; Bot I; van Puijvelde GHM; Kuiper J; Foks AC
    Cardiovasc Res; 2020 Feb; 116(2):295-305. PubMed ID: 31150053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TIGIT/CD226 axis regulates human T cell function.
    Lozano E; Dominguez-Villar M; Kuchroo V; Hafler DA
    J Immunol; 2012 Apr; 188(8):3869-75. PubMed ID: 22427644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIGIT-Fc as a Potential Therapeutic Agent for Fetomaternal Tolerance.
    Fu W; Cai R; Ma Z; Li T; Lei C; Zhao J; Hu S
    Front Immunol; 2021; 12():649135. PubMed ID: 33841433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/- mice.
    Potì F; Gualtieri F; Sacchi S; Weißen-Plenz G; Varga G; Brodde M; Weber C; Simoni M; Nofer JR
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1505-12. PubMed ID: 23640484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).
    Yasuma K; Yasunaga J; Takemoto K; Sugata K; Mitobe Y; Takenouchi N; Nakagawa M; Suzuki Y; Matsuoka M
    PLoS Pathog; 2016 Jan; 12(1):e1005372. PubMed ID: 26735971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis.
    Packard RR; Maganto-García E; Gotsman I; Tabas I; Libby P; Lichtman AH
    Circ Res; 2008 Oct; 103(9):965-73. PubMed ID: 18832748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Autophagy in CD11b
    Clement M; Raffort J; Lareyre F; Tsiantoulas D; Newland S; Lu Y; Masters L; Harrison J; Saveljeva S; Ma MKL; Ozsvar-Kozma M; Lam BYH; Yeo GSH; Binder CJ; Kaser A; Mallat Z
    Circ Res; 2019 Nov; 125(11):1019-1034. PubMed ID: 31610723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT enhances CD4
    Chen F; Xu Y; Chen Y; Shan S
    Cancer Med; 2020 May; 9(10):3584-3591. PubMed ID: 32212317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT overexpression diminishes the function of CD4 T cells and ameliorates the severity of rheumatoid arthritis in mouse models.
    Zhao W; Dong Y; Wu C; Ma Y; Jin Y; Ji Y
    Exp Cell Res; 2016 Jan; 340(1):132-8. PubMed ID: 26683997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deficiency of HIF1α in Antigen-Presenting Cells Aggravates Atherosclerosis and Type 1 T-Helper Cell Responses in Mice.
    Chaudhari SM; Sluimer JC; Koch M; Theelen TL; Manthey HD; Busch M; Caballero-Franco C; Vogel F; Cochain C; Pelisek J; Daemen MJ; Lutz MB; Görlach A; Kissler S; Hermanns HM; Zernecke A
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2316-25. PubMed ID: 26404487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of TIGIT on CD4+ T cells ameliorates immune-mediated bone marrow failure of aplastic anemia.
    Zhang T; Wang J; Zhou X; Liang R; Bai Q; Yang L; Gu H; Gao G; Dong B; Zhu H; Chen X
    J Cell Biochem; 2014 Nov; 115(11):1918-27. PubMed ID: 24905442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice.
    Foks AC; Van Puijvelde GH; Wolbert J; Kröner MJ; Frodermann V; Van Der Heijden T; Van Santbrink PJ; Boon L; Bot I; Kuiper J
    Cardiovasc Res; 2016 Aug; 111(3):252-61. PubMed ID: 27234908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions.
    Joller N; Hafler JP; Brynedal B; Kassam N; Spoerl S; Levin SD; Sharpe AH; Kuchroo VK
    J Immunol; 2011 Feb; 186(3):1338-42. PubMed ID: 21199897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
    Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
    J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.
    Poti F; Bot M; Costa S; Bergonzini V; Maines L; Varga G; Freise H; Robenek H; Simoni M; Nofer JR
    Thromb Haemost; 2012 Mar; 107(3):552-61. PubMed ID: 22234485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
    Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
    Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
    Bu DX; Tarrio M; Maganto-Garcia E; Stavrakis G; Tajima G; Lederer J; Jarolim P; Freeman GJ; Sharpe AH; Lichtman AH
    Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1100-7. PubMed ID: 21393583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmacytoid dendritic cells protect against atherosclerosis by tuning T-cell proliferation and activity.
    Daissormont IT; Christ A; Temmerman L; Sampedro Millares S; Seijkens T; Manca M; Rousch M; Poggi M; Boon L; van der Loos C; Daemen M; Lutgens E; Halvorsen B; Aukrust P; Janssen E; Biessen EA
    Circ Res; 2011 Dec; 109(12):1387-95. PubMed ID: 22021930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.